Physician
Internal Medicine
Dr. Michael M. Gottesman, MD
|
|
Give Review
Michael Gottesman practices Internal Medicine. He went to Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received awards:"Elected Member" and "Whos Who in Medicine and Healthcare". Michael M. Gottesman has written publications. He has 89 publications published with PubMed. The lastest publication is: 'Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.'
Publications
- Towards a Better Understanding of the Complexity of Cancer Drug Resistance.
- The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans.
- The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
- Modeling intrinsic heterogeneity and growth of cancer cells.
- Gil ashwell, 1916-2014.
- Uptake of Compounds That Selectively Kill Multidrug-Resistant Cells: The Copper Transporter SLC31A1 (CTR1) Increases Cellular Accumulation of the Thiosemicarbazone NSC...
- SCORHE: A novel and practical approach to video monitoring of laboratory mice housed in vivarium cage racks.
- Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells.
- The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
- Simplifying the complexity of resistance heterogeneity in metastasis.
- MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.
- Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
- Microfabricated polymeric vessel mimetics for 3-D cancer cell culture.
- Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity.
- The role of the NIH in nurturing clinician-scientists.
- MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
- The clinical relevance of cancer cell lines.
- Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
- RAB8 Enhances TMEM205-Mediated Cisplatin Resistance.
- Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions.
- Synthesis and structure-activity evaluation of isatin-?-thiosemicarbazones with improved selective activity towards multidrug-resistant cells expressing P-glycoprotein.
- Collateral sensitivity of multidrug resistant cells to the orphan drug tiopronin.
- Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivat...
- Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
- Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells.
- Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
- Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.
- Commentary: A delicate balance: weighing the effects of conflict-of-interest rules on intramural research at the National Institutes of Health.
- N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
- Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.
- Pseudovirions as vehicles for the delivery of siRNA.
- Changes in NIH criteria for tenure to reward clinical/translational teams.
- Mechanisms of multidrug resistance in cancer.
- Identification of compounds selectively killing multidrug-resistant cancer cells.
- Influence of melanosome dynamics on melanoma drug sensitivity.
- Building scientific progress without borders: nanobiology and nanomedicine in China and the U.S.
- Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.
- Structure of a multidrug transporter.
- A dual-fluorescence high-throughput cell line system for probing multidrug resistance.
- An interview with Michael M. Gottesman, M.D. Interview by Vicki Glaser.
- Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
- The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer.
- Silent (synonymous) SNPs: should we care about them?
- SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.
- Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
- Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific.
- The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
- Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
- Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
- Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane.
- P-Glycoprotein is not present in mitochondrial membranes.
- A "silent" polymorphism in the MDR1 gene changes substrate specificity.
- Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.
- Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
- Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.
- Endocytic recycling compartments altered in cisplatin-resistant cancer cells.
- Defeating drug resistance in cancer.
- Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery.
- Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.
- Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer.
- Transmembrane inhibitors of P-glycoprotein, an ABC transporter.
- Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.
- Useful tool to generate unidirectional deletion vectors by utilizing the star activity of BamHI in an NcoI-BamHI-XhoI cassette.
- Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
- Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.
- Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines.
- A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.
- Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.
- Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.
- Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells.
- Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
- The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.
- Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
- Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.
- Codominance of cisplatin resistance in somatic cell hybrids.
- P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
- Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest.
- Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.
- High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.
- Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.
- Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.
- In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.
- Mechanisms of cancer drug resistance.
- Workshop on ABC Transporters and Human Diseases.
- Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers.
- Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.
- Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).
- Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
Schools
Harvard Medical School
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
Harvard Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Susan Yuditskaya, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick G. O'Malley, MD |
|
|
Dr. Corey C. Lau, MD |
|
|
Dr. Ryan M. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shilpa Lingala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atul Rohatgi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gina S. Wei, MD |
|
|
Dr. Eric C. Greenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Havlik, MD |
|
|
Dr. Robert Yarchoan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey C. Chin, MD
This Doctor is OpenDoctor Recommended.
|